US-based technology investor Amadeus Capital Partners has planned to invest in mobile medical devices maker Inotec‘s woundcare technology, Natrox.

Inotec’s Natrox is a class II medical device which allows clinicians to prescribe pure humidified oxygen to be directly applied to a wound to heal chronic or non healing wounds.

Oxygen is said to play a key role in all cellular processes and is instrumental in healing a wound. However, about 90% of wounds suffer from a lack of oxygen which is catered to by Inotec’s easy and cost-effective Natrox.

“Being small and portable, Natrox can be used at home, as well as in hospital, alleviating pressure on stretched healthcare systems and materially improving quality of life for patients.”

Approved by the US Food and Drug Administration (FDA), Natrox is lightweight and compact, which allows a continuous oxygen therapy for patients at home or in hospital.

It can be sported under clothing during the day in the pouch provided and positioned comfortably at night.

The Natrox generator releases oxygen by electrolysis and conveys it to the oxygen delivery system (ODS), directly in contact with the wound, through a thin flexible tube.

The process involving the technology is noiseless providing a continuous supply of oxygen to the wound.

Amadeus Capital Partners investment manager Pierre Socha said: “Inotec’s proprietary technology has the potential to profoundly improve standards of care for hard-to-heal and chronic wounds, a large and growing market, which has not been disrupted since negative therapy (VAC) was launched in the 90s.

“Being small and portable, Natrox can be used at home, as well as in hospital, alleviating pressure on stretched healthcare systems and materially improving quality of life for patients.”

Amadeus Capital Partners has offered to invest on Inotec’s technology and offer the expertise to enable the company to undertake clinical trials outside the UK and to widen the scope of application of its technology.